When did LYELL IMMUNOPHARMA INC (LYEL) report earnings last quarter?
LYELL IMMUNOPHARMA INC (LYEL) last reported earnings on 3/12/2026.
LYELL IMMUNOPHARMA INC (LYEL) Earnings History & Surprises
NASDAQ:LYEL • US55083R2031
Current stock price
19.82 USD
-0.99 (-4.76%)
Last:
LYEL Earnings overview
Past quarterly earnings results for LYELL IMMUNOPHARMA INC (LYEL), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 11, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$2.27
- Revenue Estimate
- 9.69K
Last Reported
Most Recent- Release Date
- Mar 12, 2026
- Period
- Q4 / 2025
- EPS Reported
- -$7.50
- EPS Surprise
- -229.52%
- Revenue Surprise
- -51.78%
Beat Rate
Last 8 Quarters 31%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -7.50 | -2.28 | -229.52% | -87.50% | 6K | 12.444K | -51.78% | -45.45% |
| Q3 2025 | -2.13 | -2.70 | 20.98% | 37.35% | 15K | - | -55.88% | |
| Q2 2025 | -2.89 | -3.65 | 20.93% | 19.72% | 8K | - | -38.46% | |
| Q1 2025 | -3.54 | -3.67 | 3.59% | 26.25% | 7K | - | 133.33% | |
| Q4 2024 | -4.00 | -3.47 | -15.34% | - | 11K | - | -15.38% | |
| Q3 2024 | -3.40 | -4.08 | 16.67% | - | 34K | - | 36.00% | |
| Q2 2024 | -3.60 | -4.18 | 13.92% | - | 13K | - | -51.85% | |
| Q1 2024 | -4.80 | -4.28 | -12.04% | -4.35% | 3K | - | -95.38% | |
| Q4 2023 | -4.00 | -4.65 | 14.00% | -400.00% | 13K | - | -99.97% | |
| Q3 2023 | -3.40 | -5.10 | 33.33% | 39.29% | 25K | - | - | |
| Q2 2023 | -3.60 | -5.58 | 35.44% | -20.00% | 27K | - | -99.92% | |
| Q1 2023 | -4.60 | -5.78 | 20.41% | 17.86% | 65K | - | -88.18% | |
| Q4 2022 | -0.80 | -6.19 | 87.07% | 88.57% | 48.39M | 1.904M | 2,441.49% | 1,615.96% |
| Q3 2022 | -5.60 | -6.32 | 11.45% | -40.00% | 1.836M | -100.00% | -100.00% | |
| Q2 2022 | -3.00 | -6.32 | 52.56% | 83.15% | 35.74M | 1.088M | 3,184.93% | 1,258.94% |
| Q1 2022 | -5.60 | -5.85 | 4.24% | - | 550K | 1.02M | -46.08% | -77.55% |
| Q4 2021 | -7.00 | -5.61 | -24.78% | - | 2.82M | 2.907M | -2.99% | 22.08% |
| Q3 2021 | -4.00 | -5.51 | 27.38% | - | 2.76M | 2.346M | 17.65% | 157.94% |
| Q2 2021 | -17.80 | -7.45 | -139.05% | - | 2.63M | 2.295M | 14.60% | -15.71% |
| Q1 2021 | - | - | 2.45M | - | 94.44% | |||
| Q4 2020 | - | - | 2.31M | - | - | |||
| Q3 2020 | - | - | 1.07M | - | - | |||
| Q2 2020 | - | - | 3.12M | - | - | |||
| Q1 2020 | - | - | 1.26M | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
3
Average EPS beat (4)
-46.01%
Max EPS beat (4)
20.98%
Min EPS beat (4)
-229.52%
Revenue beat statistics
Revenue beat (4)
N/A
Average Revenue beat (4)
N/A
Max Revenue beat (4)
N/A
Min Revenue beat (4)
N/A
Analysis
In the last 4 quarters, LYEL has beaten EPS estimates in 3 out of 4 releases
In the last 4 quarters, LYEL reported -46.0% below the EPS estimates on average.
Related analysis
LYELL IMMUNOPHARMA INC / LYEL Earnings FAQ
Did LYEL stock beat earnings estimates in the most recent quarter?
LYELL IMMUNOPHARMA INC (LYEL) missed EPS estimates and missed revenue estimates in the most recent quarter.
Can you provide information on how often LYELL IMMUNOPHARMA INC beats earnings estimates?
In the last 4 quarters, LYELL IMMUNOPHARMA INC (LYEL) has beaten EPS estimates in 3 out of 4 releases.